Company Overview of University of California - San Diego
University of California - San Diego is an educational institution that offers undergraduate and graduate courses in Aerospace Engineering, Anthropology, Bioengineering, Computer Science & Engineering, Economics, History, Literature, and Music. The University has six colleges that include Thurgood Marshall, John Muir, Revelle, Roosevelt, Sixth, and Warren College. University of California - San Diego has endowment assets of $274 millions.
9500 Gilman Drive
301 University Center
La Jolla, CA 92093-0021
Founded in 2007
Key Executives for University of California - San Diego
Associate Vice Chancellor
Vice Chancellor of Research
Chief of the Division of Global Public Health
Director of Communications
Compensation as of Fiscal Year 2014.
University of California - San Diego Key Developments
University of California, San Diego Appoints Juan Gonzalez as Vice Chancellor for Student Affairs, Effective from September 1, 2014
Jun 19 14
Juan Gonzalez, a collaborative leader and strong student advocate, has been appointed as vice chancellor for Student Affairs at the University of California, San Diego, effective from September 1, 2014. Gonzalez has served as vice president for Student Affairs at a number of universities over a 22-year period; most recently, he held the position at the University of Texas at Austin. Gonzalez's responsibilities at UC San Diego will include the development, assessment and improvement of services that meet and support the needs of students and the university's mission. As vice chancellor for Student Affairs, Gonzalez will support UC San Diego's vision of being a student-centered, research-focused, service-oriented public university by overseeing a wide range of student services and programs. These services encompass academic enrichment, admissions and enrollment services, athletics, international education, residential life, research opportunities and more. In addition, his responsibilities will include creating a student experience that fosters the intellectual, social, ethical and personal development of students, preparing them to become engaged and constructive members of a diverse, dynamic and global society.
PaxVax Inc. Enters into Research and Development Collaboration with the University of California, San Diego to Develop a Combination Vaccine to Prevent Genital Herpes Simplex Virus Infections
Jun 10 14
PaxVax Inc. announced that it has entered into a research and development collaboration with the University of California, San Diego to develop a combination vaccine to prevent genital herpes simplex virus (HSV) infections. PaxVax will license intellectual property and work together with Deborah Spector, Ph.D., distinguished professor in the UC San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences and the university's Department of Cellular and Molecular Medicine to select the optimal vaccine combination and take this vaccine candidate into clinical trials. Financial terms of the collaboration were not disclosed. HSV is one of the most common sexually transmitted diseases in the United States and throughout the world, with approximately 750,000 new infections annually in the U.S. alone. Approximately 20% of the U.S. population is infected with HSV. There are two types of HSV, including HSV2, which is most commonly associated with genital herpes. HSV1 is generally responsible for 'fever blisters' or cold sores around the mouth and face, but can also cause genital herpes. After the initial infection, HSV becomes latent or dormant, but can reactivate periodically causing local skin lesions and the shedding of virus that can be spread by sexual contact. Prescription medicines are available to inhibit virus replication, lessen symptoms and decrease transmission to others, but a treatment does not exist to block the initial infection or onset of HSV. It has been shown that people who are infected with HSV are more susceptible to HIV infection, and thus an effective vaccine for HSV could also reduce HIV transmission rates.
Human Longevity Inc. Announces Research Agreement with University of California - San Diego
Mar 4 14
The new collaborative research agreement between Human Longevity Inc. and the University of California, San Diego represents a significant and necessary step in efforts to research and translate the potential of the human genome into novel and real treatments and therapies able to change and improve the human condition. HLI's goal is to initially sequence up to 40,000 human genomes per year, rising to 100,000 genomes annually. The data generated by HLI will be used to investigate and develop treatments for a wide array of diseases, from diabetes and obesity to conditions of the heart and liver, plus ailments related to aging and biological decline. The initial focus of the effort at UC San Diego will be cancer. UC San Diego Moores Cancer Center (MCC) will work with HLI to develop protocols and procedures to conduct comprehensive genomic sequencing of consenting MCC patients. The resulting sequence data will be analyzed by UC San Diego scientists implementing both experimental and computational approaches.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|